Indexed by：
Abstract：
HIV-1 membrane fusion plays an important role in the process that HIV-1 entrys cells. As a new treatment options targeting HIV-1 entry process, fusion inhibitors have been proposed. Peptide T20 which derived from viral envelope glycoprotein gp41, is the first and only HIV-1 fusion inhibitor approved by the FDA. Currently, a large number of prospective fusion peptides have emerged. This paper introduced the possible mechanism of fusion inhibitor, reported the current developments and innovative designs of HIV-1 membrane fusion inhibitors. © 2013 Springer-Verlag.
Keyword：
Reprint Author's Address：
Email：
Source ：
ISSN： 1680-0737
Year： 2013
Volume： 39 IFMBE
Page： 2221-2223
Language： English
Cited Count：
SCOPUS Cited Count：
ESI Highly Cited Papers on the List： 0 Unfold All
WanFang Cited Count：
Chinese Cited Count：
30 Days PV： 2
Affiliated Colleges：
